Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT. But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders.

FDA approves expanded use of radioembolization therapy for liver cancer
The added indications make the treatment the first Y-90 therapy approved for both unresectable hepatocellular carcinoma and metastatic colorectal cancer of the liver.
Post-ablation PET imaging may not be cost-effective in patients with liver metastases
Although most radiology organizations agree that [18F]FDG PET/CT can provide valuable information in these patients post-treatment, their recommendations differ on its use.
FDA approves expanded use of PET imaging agent
The product's updated indications include quantification and long-term monitoring of amyloid plaques on imaging.
'Powerful' new PET agent improves the diagnosis of triple-negative breast cancer
The agent “exhibits powerful tumor delineation” in challenging cases of determining cancer subtypes, and could potentially lead to more personalized, effective treatment strategies.
Industry partnership set to advance research on theranostics
The deal will create a Therapy Command Center to support the study and use of theranostics across Massachusetts General Hospital and its affiliated centers in bordering states.

FDA partners with Alzheimer’s advocacy groups

The FDA is collaborating with a number of Alzheimer’s groups including the Alzheimer’s Association within the community to support the development of new biomarkers and improved diagnosis.

Women’s infertility may be due to genetic uptick in male hormones

If an ovarian cell carries a certain genetic variant it could spell an excess of androgens much like testosterone in women with polycystic ovary syndrome, making it more difficult for them to conceive. This revelation could eventually lead to a diagnostic test and treatment, according to an announcement yesterday from the National Institutes of Health.

Molecular breast cancer imaging may be called on to reduce overdiagnosis

This issue isn't about false positives, it is about subjecting patients to treatment after mammography finds a small lesion, but when in all actuality that spot on the scan poses no real threat to the patient. Some cancers are never progressive and do not require serious treatment when to do so would come with its own risks and potential complications.

ABT implements first Dose on Demand Biomarker Generator in Russia

ABT Molecular Imaging has successfully implemented the first BG-75 Biomarker Generator in Russia. The project was completed in cooperation with the Diagnostic and Treatment Center of the International Institute of Biological Systems (DTC IIBS), St. Petersburg, Russia, and its U.S. representative, Owen Kane Molecular Imaging, Inc. (Owen Kane). 

Cardiovascular biomarker market could hit $7.2B by 2018

The global market for diagnostic biomarkers detecting cardiovascular disease is expected to soar steadily at a compound annual growth rate of 12.8 percent between 2013 and 2018.

Genomic research could spell new drugs for schizophrenia and other disorders

A partnership between the Broad Institute’s Stanley Center for Psychiatric Research in Cambridge, Mass., and Tetra Discovery Partners based in Grand Rapids, Mich., that pores over the human genome for specific variants in schizophrenia may make way for new pharmaceutical therapies for psychiatric disease, Tetra announced April 9.

A-synuclein SPECT agent scopes out Parkinson’s

A prospective Parkinson’s imaging agent taps into alpha-synuclein deposition in the brain, developers ICB International announced April 11.

Parkinson's gene promotes deadly protein over-production

Runaway production of proteins tripped off by a genetic mutation may be the culprit in the neurological damage associated with Parkinson’s disease, the National Institutes of Health announced yesterday.

Molecular Imaging

FDA approves expanded use of radioembolization therapy for liver cancer

Post-ablation PET imaging may not be cost-effective in patients with liver metastases

FDA approves expanded use of PET imaging agent

'Powerful' new PET agent improves the diagnosis of triple-negative breast cancer

Industry partnership set to advance research on theranostics